News

The drug, called Zubsolv, is a formulation of buprenorphine, a semisynthetic opioid derivative of thebaine, and naloxone, an opioid overdose antidote. The new low dose, 0.7mg/0.18 mg, Zubsolv

ATTR amyloidosis disease occurs due to the deposition of transthyretin in peripheral tissues. The company said study safety monitors recommended that the phase 3 trial be stopped after

Codexis will receive an $8 million payment from Merck for completion of this milestone to be paid in the fourth quarter of 2016. Codexis President and CEO John

Solabegron is a highly potent and selective beta-3 adrenoceptor agonist that is being developed for the treatment of overactive bladder (OAB). Moreover, solabegron has already demonstrated efficacy for

Teva said the divestment of the assets and operations was part of an undertaking that it made to the European Commission related to the acquisition of Actavis Generics

Brilinta was being tested against clopidogrel in 13,885 patients in 28 countries. The study, dubbed Euclid, is the largest trial of its kind in such patients and forms

TD-1473 is a novel, potent, orally administered and intestinally restricted pan-Janus kinase (JAK) inhibitor in clinical development, with the potential to treat a range of inflammatory intestinal diseases.

Under terms of the agreement, Daiichi Sankyo and AgonOx will collaborate on preclinical development of the program. Following preclinical assessment, Daiichi Sankyo has an exclusive option to research,

The deal grants Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States (‘the licensed territory’), to Summit’s utrophin modulator pipeline, including its lead